Maxillofacial Plastic and Reconstructive Surgery

  • Volume 41
  • /
  • Pages.26.1-26.7
  • /
  • 2019
  • /
  • 2288-8101(pISSN)
  • /
  • 2288-8586(eISSN)
Korean Association of Maxillofacial Plastic and Reconstructive Surgeons (대한악안면성형재건외과학회)
권호 표지
DOI QR코드

DOI QR Code

Pharmacoepidemiology and clinical characteristics of medication-related osteonecrosis of the jaw

  • Son, Hyo-Jeong (Department of Oral and Maxillofacial Surgery, School of Medicine, Ewha Womans University) ;
  • Kim, Jin-Woo (Department of Oral and Maxillofacial Surgery, School of Medicine, Ewha Womans University) ;
  • Kim, Sun-Jong (Department of Oral and Maxillofacial Surgery, School of Medicine, Ewha Womans University)
  • Received : 2019.06.11
  • Accepted : 2019.06.24
  • Published : 2019.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The aim of this study was to investigate clinical and pharmacoepidemiologic characteristics of medicationrelated osteonecrosis of the jaw. Methods: The study population is comprised of 86patients who were diagnosed with ONJ at Ewha Womans University Mokdong Hospital from 2008 to 2015. Factors for epidemiologic evaluation were gender, age, location of lesion, and clinical history. The types of bisphosphonates, duration of intake, and the amount of accumulated dose were evaluated for therapeutic response. Clinical symptoms and radiographic images were utilized for the assessment of prognosis. Results: Among the 86 patients, five were male, whereas 81 were female with mean age of 73.98 (range 45-97). Location of the lesion was in the mandible for 58 patients and maxilla in 25 patients. Three patients had both mandible and maxilla affected. This shows that the mandible is more prone to the formation of ONJ lesions compared to the maxilla. ONJ occurred in 38 cases after extraction, nine cases after implant surgery, six cases were denture use, and spontaneously in 33 cases. Seventy-six patients were taking other drugs aside from drugs indicated for osteoporosis. Most of these patients were diagnosed as osteoporosis, rheumatic arthritis, multiple myeloma, or had a history of cancer therapy. Higher weighted total accumulation doses were significantly associated with poorer prognosis (P < 0.05). Conclusion: Dose, duration, route, and relative potency of bisphosphonates are significantly associated with treatment prognosis of osteonecrosis of the jaw.

Keywords

References

  1. Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaw: a growing epidemic. J Oral Maxillofac Surg 61:1115-1117 https://doi.org/10.1016/S0278-2391(03)00720-1
  2. Kulkarni R, Cymerman J, Pick A (2014) Antiresorptive related osteonecrosis of the jaw bone (ARONJ); a single maxillofacial unit case series and analysis. Br J Oral Maxillofac Surg 52:74-82
  3. Ruggiero SL, Dodson TB, Fantasia J (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosisi of the jaw-2014 update. J Oral Maxillofac Surg 72:1938-1956 https://doi.org/10.1016/j.joms.2014.04.031
  4. Major P, Lorholary A (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy; a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19(2):558-567 https://doi.org/10.1200/JCO.2001.19.2.558
  5. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA et al (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21(21):4042-4047 https://doi.org/10.1200/JCO.2003.08.017
  6. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94(19):1458-1468 https://doi.org/10.1093/jnci/94.19.1458
  7. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M, Zoledronic acid prostate cancer study group (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96(11):879-882 https://doi.org/10.1093/jnci/djh141
  8. Khan AA, Morrison A, Hanley DA (2015) Diagnosis and management of osteonecrosis of the jaw: a systemic review and international consensus. J Bone Miner Res 30:3-23 https://doi.org/10.1002/jbmr.2405
  9. de Boissieu P, Knangaratnam L, Mahmoudi R, Morel A, Drame M, Trenque T (2017) Adjudication of osteonecrosis of the jaw in phaseIII randerminzed controlled trials of denosumab: a systematic review. Eur J Clin Pharmacol 73:517-523 https://doi.org/10.1007/s00228-017-2210-x
  10. Khan AA, Morrison A, Kendler DL (2017) Case-based review of osteonecrosis of the jaw(ONJ) and application of the international recommendations for management from the international task force on ONJ. J Clin Densitom 20:8-24 https://doi.org/10.1016/j.jocd.2016.09.005
  11. Ruggiero SL, Dodson TB, Fantasia J (2007) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw. Advisory task force on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65:369-376 https://doi.org/10.1016/j.joms.2006.11.003
  12. Aghaloo T, Goodday R, Mehrotra T (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw 2009 update. Aust Endod J 35:119-130 https://doi.org/10.1111/j.1747-4477.2009.00213.x
  13. Silverman SL, Landesberg R (2009) Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J of Med 122:33-45
  14. Mavrokokki T, Cheong A, Stein B, Goss A (2007) Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65:415-423 https://doi.org/10.1016/j.joms.2006.10.061
  15. Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG (2009) Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27:5356-5362 https://doi.org/10.1200/JCO.2009.21.9584
  16. Filleulo CE, Saussez E (2010) Bisphosphonate-induced osteonecrosis of the jaw: a review of 2400 patient cases. J Cancer Res Clin Oncol 136:1117-1124 https://doi.org/10.1007/s00432-010-0907-7
  17. Favia G, Pilolli GP, Maiorano E (2009) Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients. J Rheumatol 36:2780-2787 https://doi.org/10.3899/jrheum.090455
  18. Rodan GA, Fleisch HS (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97:2692-2699 https://doi.org/10.1172/JCI118722
  19. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M et al (2004) Long-term efficacy and and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized phase III, double-blind, placebocontrolled trial. Cancer 100(12):2613-2622 https://doi.org/10.1002/cncr.20308
  20. Benrenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC et al (2002) American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 20(17):3719-3736 https://doi.org/10.1200/JCO.2002.06.037
  21. Balica NC, Peonaru M, Stefanescu EH, Boia ER, Cl C, Baderca F et al (2016) Anterior commissure laryngeal neoplasm endoscopic management. Romanian J Morphol Embryol 57(2):715-718
  22. Sarau CA, Poenaru M, Balica NC, Baderca F (2017) Rare sinonasal lesions. Romanian J Morphol Embryol 58(4):1541-1547
  23. Balica NC, Poenary M, Cl D, Baderca F, Preda MA, lovan VC et al (2018) The management of the oropharyngeal anterior wall cancer. Romanian J Morphol Embryol 59(1):113-119
  24. Jianu DC, Jianu SN, Dan TF, Motoc AG, Poenaru M (2016) Pulsatile tinnitus caused by a dilated left petrosquamosal sinus. Romanian J Morphol Embryol 57(1):319-322
  25. Sarau CA, Lighezan DF, Doros IC (2015) The involvement of upper airway in Wigener's granulomatosis-about four cases. Romanian J Morphol Embryol 56(2):613-618
  26. Marin KC, Berdich-kun KN, Gentil F, Parente M, Natal RJ, Marin HA et al (2014) Application of a finite element model in the diagnosis process of middle ear pathologies. Romanian J Morphol Embryol 55(4):1511-1514
  27. Kimmel DB (2007) Mechanism of actions, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen containing bisphosphonates. JCLI 86:1022-1033
  28. Ruggiero SL, Fantasia J, Carlson E (2006) Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102:433-441 https://doi.org/10.1016/j.tripleo.2006.06.004
  29. Alejandro P, Luis J, Lorena G, Luis GC, Lucia GM, Tommaso C et al (2015) Epidemiology, pharmacology and clinical characterization of bisphosphonate-related osteonecrosis of the jaw. A retrospective study of 70 cases. Acta Otorrinolaringol Esp 66(3):139-147 https://doi.org/10.1016/j.otorri.2014.06.003
  30. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62(5):527-534 https://doi.org/10.1016/j.joms.2004.02.004
  31. Reid IR, Bolland MJ, Grey AB (2007) Bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity. Bone 41(3):318-320 https://doi.org/10.1016/j.bone.2007.04.196
  32. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23(34):8580-8587 https://doi.org/10.1200/JCO.2005.02.8670
  33. Bi Y, Gao Y, Ehirchiou D, Cao C, Kikuiri T, Le A et al (2010) Bisphosphonates cause osteonecrosis of the jaw like disease in mice. Am J Pathol 177(1):280-290 https://doi.org/10.2353/ajpath.2010.090592
  34. Hokugo A, Christensen R, Chung EM, Sung EC, Felsenfeld AL, Sayre JW et al (2010) Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats. J Bone Miner Res 25(6):1337-1349 https://doi.org/10.1002/jbmr.23
  35. Mortensen M, Lawson W, Montazem A (2007) Osteonecrosis of the jaw associated with bisphosphonate use: presentation of seven cases and literature review. Laryngoscope 117(1):30-34 https://doi.org/10.1097/01.mlg.0000240885.64568.9e
  36. Lo JC, O'Ryan FS, Gordon NP, Yang J, Hul RL (2010) Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 68:243-253 https://doi.org/10.1016/j.joms.2009.03.050
  37. Ruggiero SL, Mehrotra B (2004) Ten years of alendronate treatment for osteopososis in postmenopausal women. New Engl J Med 351:190-198 https://doi.org/10.1056/NEJM200407083510218
  38. Malden N, Lopes V (2002) An epidemiological study of alendronaterelated osteonecrosis of the jaws. A case series from the south-east of Scotland with attention given to case definition and prevalence. J Bone Miner Metab 30(2):171-182 https://doi.org/10.1007/s00774-011-0299-z
  39. Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M et al (2010) The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc 141(11):1365-1370 https://doi.org/10.14219/jada.archive.2010.0082
  40. Francesco B (2013) Bisphosphonate-related osteonecrosis of the jaws (BRONJ). Oral Patol Oral Cir Buccal 18(5):752-758
  41. Saussez S, Javadian R, Hupin C, Magremanne M, Chantrain G (2009) Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: a Belgian case series. Laryngoscope 119:323-329 https://doi.org/10.1002/lary.20076
  42. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM et al (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302(3):1055-1061 https://doi.org/10.1124/jpet.102.035295
  43. Vescovi P, Merigo E, Meleti M, Manfredi M, Guidotti R, Nammour S (2007) Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients. J Oral Pathol Med 41(3):214-221 https://doi.org/10.1111/j.1600-0714.2011.01091.x
  44. Fedele S, Porter SR, D'Aiuto F, Aljohani S, Vescovi P (2010) Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 123:1060-1064 https://doi.org/10.1016/j.amjmed.2010.04.033
  45. Mawardi H, Treister N, Richardson P, Anderson K, Munshi N (2009) Sinus tracts an early sign of bisphosphonateassociated osteonecrosis of the jaws. J Oral Maxillofac Surg 67:593-601 https://doi.org/10.1016/j.joms.2008.09.031
  46. Bagan JV, Jimenez Y, Diaz JM, Murillo J, Sanchis JM (2009) Osteonecrosis of the jaws in intravenous bisphosphonate use: proposal for a modification of the clinical classification. Oral Oncol 45:645-646 https://doi.org/10.1016/j.oraloncology.2008.05.011
  47. Ficarra G, Beninati F (2007) Bisphosphonate-related osteonecrosis of the jaw; the point of view of the oral pathologist. Clin Cases Miner Bone Metab 4:53-57
  48. Otto S, Abu-Id MH, Fedele S, Warnke PH, Becker ST, Kolk A (2011) Osteoporosis and bisphosphonates-related osteonecrosis of the jaw; not just a sporadic coincidence; a muli-centre study. J Craniomaxillofac Surg 39:272-277 https://doi.org/10.1016/j.jcms.2010.05.009
  49. Neville B, Damm DD, Allen C, Chi A (2016) Oral and maxillofacila pathology. Elsevier, Ed 4, St. Louis, Amsterdam
  50. Hellstein JW (2011) Managing the care of patients receiving antiresorptive therapy for prevention-related osteonecrosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 142:1243-1251 https://doi.org/10.14219/jada.archive.2011.0108
  51. Ramaglia L (2018) Stage-specific therapeutic strategies of medication related osteonecrosis of the jaw; a systematic review and meta-analysis of the drug suspension protocol. Clin Oral Investing 22:597-615 https://doi.org/10.1007/s00784-017-2325-6

Cited by

  1. Increased Level of Vascular Endothelial Growth Factors by 4-hexylresorcinol is Mediated by Transforming Growth Factor-β1 and Accelerates Capillary Regeneration in the Burns in Diabetic Animals vol.21, pp.10, 2019, https://doi.org/10.3390/ijms21103473
  2. In vitro effects of alendronate on fibroblasts of the human rotator cuff tendon vol.21, 2020, https://doi.org/10.1186/s12891-019-3014-1
  3. Immunomodulation for maxillofacial reconstructive surgery vol.42, 2019, https://doi.org/10.1186/s40902-020-00249-4
  4. Gradual, but Not Sudden, Dose-Dependent Increase of ONJ Risk With Bisphosphonate Exposure: A Nationwide Cohort Study in Women With Osteoporosis vol.12, 2021, https://doi.org/10.3389/fendo.2021.774820
  5. Is implant surgery a risk factor for osteonecrosis of the jaw in older adult patients with osteoporosis? A national cohort propensity score‐matched study vol.32, pp.4, 2019, https://doi.org/10.1111/clr.13713
  6. Various Therapeutic Methods for the Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) and Their Limitations: A Narrative Review on New Molecular and Cellular Therapeutic Approaches vol.10, pp.5, 2021, https://doi.org/10.3390/antiox10050680